Healthcare Wrap: Revenue Winners Rise as Trial Stocks Split on Results

• Cleo Diagnostics, Chimeric and Orthocell were the week’s biggest movers by magnitude
• Sales contracts and revenue growth drove gains for Cyclopharm, Memphasys and Microba
• Capital raisings and debt funding stayed central as drug developers funded late-stage programs
• US regulatory and commercial milestones remained a key reason investors paid attention